LT3498730T - Pelės su humanizuotais fc gama r - Google Patents

Pelės su humanizuotais fc gama r

Info

Publication number
LT3498730T
LT3498730T LTEP19154880.9T LT19154880T LT3498730T LT 3498730 T LT3498730 T LT 3498730T LT 19154880 T LT19154880 T LT 19154880T LT 3498730 T LT3498730 T LT 3498730T
Authority
LT
Lithuania
Prior art keywords
humanized
mice
gamma
Prior art date
Application number
LTEP19154880.9T
Other languages
English (en)
Inventor
Lynn Macdonald
Naxin Tu
Cagan Gurer
Sean Stevens
Andrew Murphy
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43601078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3498730(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of LT3498730T publication Critical patent/LT3498730T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
LTEP19154880.9T 2009-12-21 2010-12-17 Pelės su humanizuotais fc gama r LT3498730T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28856209P 2009-12-21 2009-12-21

Publications (1)

Publication Number Publication Date
LT3498730T true LT3498730T (lt) 2026-03-25

Family

ID=43601078

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP19154880.9T LT3498730T (lt) 2009-12-21 2010-12-17 Pelės su humanizuotais fc gama r
LTEP10791039.0T LT2516457T (lt) 2009-12-21 2010-12-17 Pelė su humanizuotu fc gama r

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP10791039.0T LT2516457T (lt) 2009-12-21 2010-12-17 Pelė su humanizuotu fc gama r

Country Status (27)

Country Link
US (9) US8658154B2 (lt)
EP (4) EP4706388A2 (lt)
JP (4) JP5595517B2 (lt)
KR (4) KR102178064B1 (lt)
CN (2) CN104232589B (lt)
AU (3) AU2010339863B2 (lt)
CA (2) CA3000246C (lt)
CY (1) CY1120316T1 (lt)
DK (2) DK2516457T3 (lt)
ES (2) ES3062012T3 (lt)
FI (1) FI3498730T3 (lt)
HK (1) HK1257001A1 (lt)
HR (2) HRP20260349T1 (lt)
HU (1) HUE038684T2 (lt)
IL (4) IL220365A (lt)
LT (2) LT3498730T (lt)
MY (1) MY156743A (lt)
NO (1) NO2516457T3 (lt)
PL (2) PL3498730T3 (lt)
PT (2) PT3498730T (lt)
RS (2) RS57280B1 (lt)
RU (1) RU2549695C2 (lt)
SG (3) SG10201408415PA (lt)
SI (2) SI2516457T1 (lt)
SM (2) SMT201800296T1 (lt)
TR (1) TR201808011T4 (lt)
WO (1) WO2011084664A1 (lt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3498730T3 (pl) 2009-12-21 2026-04-07 Regeneron Pharmaceuticals, Inc. Humanizowane myszy fc gamma r
WO2013063556A1 (en) 2011-10-28 2013-05-02 Regeneron Pharmaceuticals, Inc. Humanized il-6 and il-6 receptor
BR112014007946A2 (pt) * 2011-11-01 2017-04-11 Roche Glycart Ag animal transgênico não humano, descendente, linhagem de células, explante, utilização, método para a determinação da eficácia de um anticorpo e método para a avaliação do risco potencial da segurança dos anticorpos terapêuticos
CA2887706C (en) * 2012-11-05 2022-08-02 Regeneron Pharmaceuticals Genetically modified non-human animals and methods of use thereof
EP3418379B1 (en) 2013-09-18 2020-12-09 Kymab Limited Methods, cells & organisms
ES2715949T3 (es) * 2013-10-15 2019-06-07 Regeneron Pharma Animales con IL-15 humanizada
US9546384B2 (en) 2013-12-11 2017-01-17 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a mouse genome
KR102276752B1 (ko) * 2014-03-21 2021-07-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
HUE051088T2 (hu) 2014-04-08 2021-03-01 Regeneron Pharma Humanizált FC-gamma receptorokkal rendelkezõ nem humán élõlények
US9497945B2 (en) 2014-05-30 2016-11-22 Regeneron Pharmaceuticals, Inc. Humanized dipeptidyl peptidase IV (DPP4) animals
HUE052606T2 (hu) * 2014-12-09 2021-05-28 Regeneron Pharma Humanizált differenciációs klaszter 274 génnel rendelkezõ nem humán állatok
KR102658190B1 (ko) * 2015-04-13 2024-04-17 리제너론 파마슈티칼스 인코포레이티드 인간화된 sirpa-il15 녹인 마우스 및 이의 이용 방법
CA2984413A1 (en) * 2015-04-30 2016-11-03 Institute Of Immunology Co., Ltd. Transgenic non-human animal expressing human specific molecule and human fc.gamma. receptor family
IL323024A (en) 2016-05-20 2025-10-01 Regeneron Pharma Methods for breaking immunological tolerance using multiple guide RNAs
US11879014B2 (en) * 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
KR20250121150A (ko) 2018-03-26 2025-08-11 리제너론 파마슈티칼스 인코포레이티드 치료제를 시험하기 위한 인간화된 설치류
WO2020067199A1 (ja) * 2018-09-27 2020-04-02 公益財団法人実験動物中央研究所 免疫不全マウス
JP6935383B2 (ja) * 2018-09-27 2021-09-15 公益財団法人実験動物中央研究所 免疫不全マウス
JP2022520819A (ja) 2019-02-22 2022-04-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 遺伝子改変ナトリウムチャネルを有する齧歯類およびその使用方法
CN113614238B (zh) * 2019-03-28 2024-10-22 公益财团法人实中研 免疫缺陷小鼠
WO2022132943A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
US20240081301A1 (en) * 2021-02-02 2024-03-14 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric fcrn

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3740089A (en) * 1988-05-27 1989-12-12 Schering Biotech Corporation Human fc-gamma receptor iii
ATE300615T1 (de) * 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5258359A (en) * 1991-08-02 1993-11-02 Monsanto Company Glyphosant-containing herbicidal compositions comprising acetylenic diol rainfastness enhancing agents
EP0663952A4 (en) 1992-09-11 1997-06-11 Univ California Transgenic non-human animals having targeted lymphocyte transduction genes.
US5877396A (en) * 1993-04-23 1999-03-02 Sloan Kettering Institute For Cancer Research Mice mutant for functional Fc receptors and method of treating autoimmune diseases
US6111166A (en) * 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US5899312A (en) * 1997-07-22 1999-05-04 Lucent Technologies Inc Anti-fraud string grabbing device
US6676927B1 (en) 1999-01-20 2004-01-13 The Rockefeller University Animal model and methods for its use in the selection of cytotoxic antibodies
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CA2399940A1 (en) 2000-04-13 2001-10-25 The Rockefeller University Enhancement of antibody-mediated immune responses
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
AU2002222951A1 (en) 2000-07-18 2002-01-30 Geoff D. Koch Apparatus and method for maintaining control of a drilling machine
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
FR2822161B1 (fr) 2001-03-15 2003-09-19 Genoway Cellule et animal transgenique modelisant les reponses humaines allergiques mediees par les ige, et leurs utilisations
JP4653915B2 (ja) * 2001-10-29 2011-03-16 独立行政法人科学技術振興機構 全身性エリテマトーデスモデル非ヒト動物
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7351875B2 (en) * 2002-06-07 2008-04-01 Trillium Therapeutics, Inc. FcγRIIa transgenic animal model for autoimmune disease
JP2004147535A (ja) * 2002-10-29 2004-05-27 Japan Science & Technology Agency ギラン・バレー症候群及び／又はフィッシャー症候群発症モデル非ヒト動物
KR20050084317A (ko) * 2002-12-16 2005-08-26 제넨테크, 인크. 인간 ｃｄ２０ 및(또는) ｃｄ１６을 발현하는 트랜스제닉마우스
FR2858235B1 (fr) * 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
CA2552788C (en) * 2004-01-12 2013-09-24 Applied Molecular Evolution, Inc. Fc region variants
AU2005295269B2 (en) 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
CA2644903A1 (en) 2006-03-10 2007-09-20 Macrogenics, Inc. Identification and engineering of antibodies with variant heavy chains and methods of using same
US20080003225A1 (en) 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
KR101456728B1 (ko) * 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
HU0700534D0 (en) * 2006-11-24 2007-10-29 Mezoegazdasagi Biotechnologiai Transgenic animal with enhanced immune response and method for the preparation thereof
NZ583019A (en) 2007-07-31 2011-05-27 Regeneron Pharma Human antibodies to human cd20 and method of using thereof
CA2708776A1 (en) * 2007-12-10 2009-06-18 Aliva Biopharmaceuticals, Inc. Methods for sequential replacement of targeted region by homologous recombination
EP2262898B1 (en) 2008-03-07 2018-01-24 Regeneron Pharmaceuticals, Inc. Es cell-derived mice from diploid host embryo injection
US20110142857A1 (en) * 2008-07-23 2011-06-16 Rappaport Family Institue For Reseach In The Madical Sciences Efron Street Methods of altering peripheral b cell populations and uses thereof
US8883496B2 (en) * 2009-12-21 2014-11-11 Regeneron Phamaceuticals, Inc. Humanized FcgR mice
PL3498730T3 (pl) 2009-12-21 2026-04-07 Regeneron Pharmaceuticals, Inc. Humanizowane myszy fc gamma r

Also Published As

Publication number Publication date
SG10202011814TA (en) 2021-01-28
CN104232589B (zh) 2018-04-27
JP2014209923A (ja) 2014-11-13
PL2516457T3 (pl) 2018-08-31
US20140154701A1 (en) 2014-06-05
US20150313195A1 (en) 2015-11-05
TR201808011T4 (tr) 2018-06-21
US8658154B2 (en) 2014-02-25
IL261257A (en) 2018-10-31
KR102092744B1 (ko) 2020-03-24
US12036288B2 (en) 2024-07-16
CA2784953A1 (en) 2011-07-14
JP2013514778A (ja) 2013-05-02
JP5595517B2 (ja) 2014-09-24
CA3000246C (en) 2021-05-25
CY1120316T1 (el) 2019-07-10
JP5891259B2 (ja) 2016-03-22
EP4706388A2 (en) 2026-03-11
RS67844B1 (sr) 2026-03-31
HRP20180911T1 (hr) 2018-07-13
SI3498730T1 (sl) 2026-03-31
US20200061213A1 (en) 2020-02-27
EP3336102A2 (en) 2018-06-20
EP3498730A1 (en) 2019-06-19
CN104232589A (zh) 2014-12-24
US20120260357A1 (en) 2012-10-11
AU2010339863A1 (en) 2012-07-12
AU2010339863B2 (en) 2014-07-17
US20110154512A1 (en) 2011-06-23
FI3498730T3 (fi) 2026-03-12
AU2014210646A1 (en) 2014-08-28
KR20180058860A (ko) 2018-06-01
PL3498730T3 (pl) 2026-04-07
JP2016093201A (ja) 2016-05-26
SG10201408415PA (en) 2015-01-29
PT2516457T (pt) 2018-06-12
JP2014132909A (ja) 2014-07-24
DK2516457T3 (en) 2018-06-18
IL271083A (en) 2020-01-30
IL220365A (en) 2016-11-30
JP6073840B2 (ja) 2017-02-01
US10426848B2 (en) 2019-10-01
US20180015185A1 (en) 2018-01-18
US20240424145A1 (en) 2024-12-26
KR20120102138A (ko) 2012-09-17
IL242719A (en) 2017-09-28
WO2011084664A1 (en) 2011-07-14
SG181690A1 (en) 2012-07-30
EP3498730B1 (en) 2026-01-28
KR20190045404A (ko) 2019-05-02
PT3498730T (pt) 2026-02-18
KR102178064B1 (ko) 2020-11-12
KR101973524B1 (ko) 2019-09-02
RU2549695C2 (ru) 2015-04-27
HK1257001A1 (en) 2019-10-11
SMT201800296T1 (it) 2018-07-17
AU2014210645B2 (en) 2016-05-19
RU2012131296A (ru) 2014-01-27
NO2516457T3 (lt) 2018-08-11
HUE038684T2 (hu) 2018-11-28
US11020495B2 (en) 2021-06-01
IL261257B (en) 2019-12-31
AU2014210645A1 (en) 2014-08-28
US9056130B2 (en) 2015-06-16
SMT202600074T1 (it) 2026-03-09
ES3062012T3 (en) 2026-04-08
CN102762590A (zh) 2012-10-31
MY156743A (en) 2016-03-31
CA3000246A1 (en) 2011-07-14
CA2784953C (en) 2018-05-22
ES2671188T3 (es) 2018-06-05
HRP20260349T1 (hr) 2026-04-24
US9089599B2 (en) 2015-07-28
SI2516457T1 (en) 2018-08-31
RS57280B1 (sr) 2018-08-31
KR101862277B1 (ko) 2018-06-01
US8658853B2 (en) 2014-02-25
US9687566B2 (en) 2017-06-27
EP2516457B9 (en) 2021-09-29
US20140157445A1 (en) 2014-06-05
EP2516457A1 (en) 2012-10-31
KR20200033981A (ko) 2020-03-30
CN102762590B (zh) 2015-11-25
DK3498730T3 (da) 2026-02-23
US20210346522A1 (en) 2021-11-11
LT2516457T (lt) 2018-06-11
EP2516457B1 (en) 2018-03-14
EP3336102A3 (en) 2018-08-01
IL220365A0 (en) 2012-08-30
AU2014210646B2 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
ES3062012T3 (en) Humanized fc gamma r mice
IL215041A0 (en) Optimized fc variants
GB201000064D0 (en) Humanized antibodies
IL217919A0 (en) Humanized anti-cdcp1 antibodies
PL4398245T3 (pl) Dekoder wykorzystujący kasowanie aliasingu w przód
GB201005402D0 (en) Data input
EP2636040A4 (en) BACK COPY OPERATIONS
ZA201206835B (en) New humanized anti-cd20 monoclonal antibory
EP2582987A4 (en) FIXING MECHANISM
AU331840S (en) Stylus
PL2560256T3 (pl) Rurka ochronna
GB0914116D0 (en) Stylus assembly
GB201109205D0 (en) Urine shield
GB2483913B (en) Pipe attachment
IL209253A0 (en) Attachment mechanism
TWM388311U (en) Cleaning pen
GB201010834D0 (en) Digger hand
AU5294P (en) FlatspathGL Acacia spathulifolia
GB201005552D0 (en) Hand held information screen
GB201019885D0 (en) Improved stylus
PH32010000259S1 (en) Tube
GB0903969D0 (en) Selection interface
PL119189U1 (pl) Parawan
GB201004037D0 (en) Cytoxic compounds
GB201014679D0 (en) Linked/over lapping inner tubes